Pathophysiological response to hypoxia - From the molecular mechanisms of malady to drug discovery: Drug discovery for targeting the tumor microenvironment

Journal of Pharmacological Sciences

Volumn 115, Issue 4, 2011, Pages 446-452

  Nagasawa, Hideko ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Bioreductive activation; Hypoxia; Hypoxia inducible factor (HIF) 1; Tumor microenvironment

Indexed keywords

2 NITROIMIDAZOLE; 4 [BIS(2 CHLOROETHYL)OXIDOAMINO]PHENYLALANINE; AMPHOTERICIN B; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; APAZIQUONE; BANOXANTRONE; BORTEZOMIB; DACINOSTAT; DIGOXIN; ECHINOMYCIN; EZN 2968; GPU 231; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; PHENFORMIN; PRODRUG; RP 104; TANESPIMYCIN; TEMSIROLIMUS; TIRAPAZAMINE; TOPOTECAN; TRETAZICAR; TX 1102; TX 402; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER RESISTANCE; CANCER THERAPY; CELL HYPOXIA; DRUG EFFICACY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; NONHUMAN; PROTEIN FUNCTION; PROTEIN TARGETING; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; UNFOLDED PROTEIN RESPONSE;

EID: 79954991372     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.10R25FM     Document Type: Short Survey

References (32)

1. Semenza GL. Regulation of oxygen homeostasis by hypoxia-inducible factor 1. Physiology (Bethesda). 2009;24:97-106.
2. Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer. 2008;8:851-864.
3. Ebbesen P, Pettersen EO, Gorr TA, Jobst G, Williams K, Kieninger J, et al. Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies. J Enzyme Inhib Med Chem. 2009;24 Suppl 1:1-39.
4. Nagasawa H, Uto Y, Kirk KL, Hori H. Design of hypoxia-targeting drugs as new cancer chemotherapeutics. Biol Pharm Bull. 2006;29:2335-2342. (Pubitemid 44885846)
5. Ahn GO, Brown M. Targeting tumors with hypoxia-activated cytotoxins. Front Biosci. 2007;12:3483-3501.
6. Kizaka-Kondoh S, Konse-Nagasawa H. Significance of nitroimidazole compounds and hypoxia-inducible factor-1 for imaging tumor hypoxia. Cancer Sci. 2009;100:1366-1373.
7. Chen Y, Hu L. Design of anticancer prodrugs for reductive activation. Med Res Rev. 2009;29:29-64.
8. Nagasawa H, Mikamo N, Nakajima Y, Matsumoto H, Uto Y, Hori H. Antiangiogenic hypoxic cytotoxin TX-402 inhibits hypoxia-inducible factor 1 signaling pathway. Anticancer Res. 2003;23:4427-4434. (Pubitemid 37474896)
9. Cho H, Ackerstaff E, Carlin S, Lupu ME, Wang Y, Rizwan A, et al. Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia. Neoplasia. 2009;11:247-259.
10. Robinson SP, Griffiths JR. Current issues in the utility of 19F nuclear magnetic resonance methodologies for the assessment of tumour hypoxia. Philos Trans R Soc Lond B Biol Sci. 2004; 359:987-996. (Pubitemid 38784084)
11. Padhani A. PET imaging of tumour hypoxia. Cancer Imaging. 2006;6:S117-S121.
12. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3:721-732. (Pubitemid 37328811)
13. Rapisarda A, Uranchimeg B, Scudiero DA, Selby M, Sausville EA, Shoemaker RH, et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 2002;62:4316-4324. (Pubitemid 34827288)
14. Lin X, David CA, Donnelly JB, Michaelides M, Chandel NS, Huang X, et al. A chemical genomics screen highlights the essential role of mitochondria in HIF-1 regulation. Proc Natl Acad Sci U S A. 2008;105:174-179.
15. Semenza GL. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today. 2007;12:853-859. (Pubitemid 47554628)
16. Melillo G. Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev. 2007;26:341-352. (Pubitemid 47101663)
17. Melillo G. Hypoxia-inducible factor 1 inhibitors. Methods Enzymol. 2007;435:385-402.
18. Lee K, Zhang H, Qian DZ, Rey S, Liu JO, Semenza GL. Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc Natl Acad Sci U S A. 2009;106:17910-17915.
19. Shin DH, Chun YS, Lee DS, Huang LE, Park JW. Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood. 2008; 111:3131-3136.
20. Onnis B, Rapisarda A, Melillo G. Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med. 2009;13:2780-2786.
21. Ratcliffe PJ. HIF-1 and HIF-2: working alone or together in hypoxia? J Clin. Invest. 2007;117:862-865.
22. Warnecke C, Weidemann A, Volke M, Schietke R, Wu X, Knaup KX, et al. The specific contribution of hypoxia-inducible factor-2alpha to hypoxic gene expression in vitro is limited and modulated by cell type-specific and exogenous factors. Exp Cell Res. 2008;314:2016-2027.
23. Biswas S, Troy H, Leek R, Chung YL, Li JL, Raval RR, et al. Effects of HIF-1α and HIF-2α on growth and metabolism of clear-cell renal cell carcinoma 786-0 xenografts. J Oncol. 2010;2010:757908.
24. Zhu GQ, Tang YL, Li L, Zheng M, Jiang J, Li XY, et al. Hypoxia inducible factor 1α and hypoxia inducible factor 2α play distinct and functionally overlapping roles in oral squamous cell carcinoma. Clin Cancer Res. 2010;16:4732-4741.
25. 2 availability on human cancer. Nat Rev Cancer. 2008;8:967-975.
26. Yeung SJ, Pan J, Lee MH. Roles of p53, MYC and HIF-1 in regulating glycolysis - the seventh hallmark of cancer. Cell Mol Life Sci. 2008;65:3981-3999.
27. Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res. 2009;15: 6479-6483.
28. Zhivotovsky B, Orrenius S. The Warburg effect returns to the cancer stage. Sem Cancer Biol. 2009;19:1-3.
29. Liu L, Cash TP, Jones RG, Keith B, Thompson CB, Simon MC. Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol Cell. 2006;21:521-531. (Pubitemid 43228007)
30. Healy SJ, Gorman AM, Mousavi-Shafaei P, Gupta S, Samali A. Targeting the endoplasmic reticulum-stress response as an anticancer strategy. Eur J Pharmacol. 2009;625:234-246.
31. Park HR, Tomida A, Sato S, Tsukumo Y, Yun J, Yamori T, et al. Effect on tumor cells of blocking survival response to glucose deprivation. J Natl Cancer Inst. 2004;96:1300-1310. (Pubitemid 39264119)
32. Saito S, Furuno A, Sakurai J, Sakamoto A, Park HR, Shin-Ya K, et al. Chemical genomics identifies the unfolded protein response as a target for selective cancer cell killing during glucose deprivation. Cancer Res. 2009;69:4225-4234.